Notice of the National Drug Administration Drug Trial Center on the Issue of guidelines for the design of clinical trials of liraglutide injectable biosimilars (No. 3 of 2020)
-
Last Update: 2020-07-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
To guide the clinical development of liraglutide injection biosimilars in China, and to provide referencetechnical standards, with the deployment of the National Drug Administration, the Drug Review Center has organized the Development of guidelines for the design of clinical trials of liraglutide injection biosimilars (see annex 1) and its drafting instructions (see annex 2)In accordance with the requirements of the Notice of the General Division of the State Drug Administration on the Procedures for the Issuance of Technical Guidelines for the Issuance of Drugs (FDA No9 of 2020), it is hereby issued with the approval of the State Drug Administrationhereby hereby announceAnnex 1Ofaluride Injector Biosimilar Clinical Trials Guidelines.pdfAnnex 2 Drafting Notes for the Design of Clinical Trials of Liraglutide Injectable Biosimilars.pdf.pdf.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
